Antisense therapies for cancer: Bridging the pharmacogenomic divide

By contrast to other therapeutic approaches, the druggable universe is not limited with antisense technology as these inhibitors can be rationally designed based on sequence information alone. Recent clinical data have demonstrated proof of mechanism and clinical benefit for antisense drugs in many disease areas including cancer. Together with recent advances in antisense chemistry these findings suggest that this technology is now poised to emerge as a key therapeutic modality to bridge the ever growing pharmacogenomic divide in cancer drug discovery.